Hot Topics
Wed. May 23, 2018 1:20 PM - 3:10 PM Room 9 (Royton Sapporo / Regent Hall （2F）)
Chair: Takanori Yokota(Department of Neurology and Neurological Science,Tokyo Medical and Dental University, Japan), Yoshitsugu Aoki(Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP), Japan)
Nucleic Acids Therapeutics Society of Japan
First antisense oligonucleotide drug, Nesinersen, was approved for spinal muscular atrophy by FDA in December, 2017. Recent progress of basic science and clinical application of oligonucleotide drugs are reviewed and its future development is discussed.
○Punit P. Seth (Ionis Pharmaceuticals, Inc., Canada)
Schedule
Like
)
○Tatsushi Toda (Department of Neurology, Graduate School of Medicine, The University of Tokyo, Japan)
Schedule
Like
)
○Tetsuya Nagata (Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Japan)
Schedule
Like
)
○Shinichi Torii (Biogen Japan Ltd., Japan)
Schedule
Like
)